Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS®

We have advised Theramex, a leading global speciality pharmaceutical company dedicated to women's health, on its exclusive licensing agreement with Radius Health, Inc.

Theramex has entered into an exclusive licensing agreement with Radius Health Inc., for the rights to commercialise ELADYNOS® (abaloparatide), a novel bone forming agent indicated for the treatment of osteoporosis in postmenopausal women at increased risk of fractures.

The in-licensing agreement enables Theramex to commercialise and distribute ELADYNOS® on an exclusive basis in the European Economic Area, the United Kingdom, Australia and Brazil.

Theramex supports women at different stages of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause, and osteoporosis. By entering into a partnership with Radius, this agreement builds on the company's expanding portfolio and aligns to its mission to reduce fracture risks for postmenopausal women suffering from osteoporosis.

Commenting on the transaction Life Sciences Partner at Taylor Wessing, Colin McCall said: "Theramex helps women across the globe to live better lives and this agreement allows Theramex to continue its mission in providing women with the right solution when they need it. We are pleased to be a longstanding partner of Theramex and we look forward to seeing its further successes."

Theramex's Legal Director, Henrietta Clement said: "Theramex has again shown its commitment to women and the care and good management of bone health, by adding this important product to our Osteoporosis franchise. Colin and Charlie’s assistance was critical in getting us over the line within an extremely tight timeline and they did an excellent job in providing insightful advice, drawing on their considerable life sciences licensing expertise."

The team was led by partner Colin McCall and senior associate Charlie Adams.